February 13, 2018 / 12:30 PM / 12 days ago

BRIEF-Charles River Laboratories To Buy MPI Research For About $800 Mln

Feb 13 (Reuters) - Charles River Laboratories International Inc:

* CHARLES RIVER LABORATORIES TO ACQUIRE MPI RESEARCH

* CHARLES RIVER LABORATORIES INTERNATIONAL INC - DEAL FOR APPROXIMATELY $800 MILLION

* CHARLES RIVER LABORATORIES - DEAL EXPECTED TO BE ACCRETIVE TO NON-GAAP EPS BY APPROXIMATELY $0.25 IN 2018 AND APPROXIMATELY $0.60 IN 2019​

* CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍FOR 2017, MPI IS EXPECTED TO GENERATE ANNUAL REVENUE OF APPROXIMATELY $240 MILLION​

* CHARLES RIVER LABORATORIES INTERNATIONAL - ‍EXPECTS TO GENERATE OPERATIONAL SYNERGIES AS RESULT OF DEAL, WITH BENEFITS TOTALING $13 TO $16 MILLION BY END OF 2019​

* CHARLES RIVER LABORATORIES - DEAL EXPECTED TO ADD $170 TO $190 MILLION TO CHARLES RIVER‘S 2018 CONSOLIDATED REVENUE BASED ON ANTICIPATED TIMING OF CLOSE​

* CHARLES RIVER LABORATORIES INTERNATIONAL - ‍ACQUISITION & ASSOCIATED FEES ARE EXPECTED TO BE FINANCED THROUGH AN EXPANSION OF CO‘S CREDIT FACILITY & CASH​

* CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍COMPANY IS EVALUATING FIXED-RATE DEBT FINANCING ALTERNATIVES WHICH COULD BE USED TO FINANCE ACQUISITION​

* CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍ACQUISITION IS EXPECTED TO ADD $260 TO $280 MILLION TO 2019 CONSOLIDATED REVENUE​

* CHARLES RIVER LABORATORIES INTERNATIONAL INC - DEAL,ASSOCIATED FEES EXPECTED TO BE FINANCED THROUGH EXPANSION OF CHARLES RIVER‘S CREDIT FACILITY, CASH​

* CHARLES RIVER LABORATORIES - ‍EVALUATING FIXED-RATE DEBT FINANCING ALTERNATIVES WHICH COULD BE USED TO FINANCE DEAL AND FOR GENERAL CORPORATE PURPOSES​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below